{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:58:56Z","timestamp":1794650336179,"version":"4.9.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.eururo.2017.11.038","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T08:43:12Z","timestamp":1513413792000},"page":"715-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting"],"prefix":"10.1016","volume":"73","author":[{"given":"Jun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Burnstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Cherkasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"De Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Heemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Kittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Matusik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Plymate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Sawyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Selth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Zoubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Dehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh V.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.11.038_bib0305","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.11.038_bib0310","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.11.038_bib0315","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.11.038_bib0320","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.11.038_bib0325","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","article-title":"Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level","volume":"67","author":"Karantanos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0330","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2017.11.038_bib0335","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2017.11.038_bib0340","first-page":"178","article-title":"Decoding the androgen receptor splice variants","volume":"2","author":"Lu","year":"2013","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0345","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/1008-682X.178490","article-title":"Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer","volume":"18","author":"Luo","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.eururo.2017.11.038_bib0350","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1093\/nar\/gkv262","article-title":"Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies","volume":"43","author":"Chan","year":"2015","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0355","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","article-title":"Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance","volume":"23","author":"Kohli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0360","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/pros.21382","article-title":"A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities","volume":"71","author":"Hu","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2017.11.038_bib0365","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2017.11.038_bib0370","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0375","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1158\/1078-0432.CCR-13-1863","article-title":"Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer","volume":"20","author":"Yu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0380","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.11.038_bib0385","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-16-0205","article-title":"Analytic validation of RNA in situ hybridization (RISH) for AR and AR-V7 expression in human prostate cancer","volume":"22","author":"Guedes","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0390","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1078-0432.CCR-16-0237","article-title":"Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer","volume":"23","author":"Saylor","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0395","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2016.03.049","article-title":"Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer","volume":"70","author":"Welti","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0400","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2017.08.009","article-title":"Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer","volume":"73","author":"Zhu","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0405","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/0008-5472.CAN-15-2186","article-title":"Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells","volume":"76","author":"Ferraldeschi","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0410","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0415","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","article-title":"Serial blood-based analysis of AR-V7 in men with advanced prostate cancer","volume":"26","author":"Nakazawa","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0420","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","article-title":"Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells","volume":"68","author":"Onstenk","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0425","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0430","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients","volume":"71","author":"Del Re","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0435","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","article-title":"Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer","volume":"23","author":"Qu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0440","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.juro.2016.06.094","article-title":"AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate","volume":"197","author":"Todenhofer","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0445","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.juro.2016.06.095","article-title":"A whole blood assay for AR-V7 and ARv567es in patients with prostate cancer","volume":"196","author":"Liu","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0450","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.eururo.2017.07.024","article-title":"AR-V7 in peripheral whole blood of patients with castration-resistant prostate cancer: association with treatment-specific outcome under abiraterone and enzalutamide","volume":"72","author":"Seitz","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0455","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00345-017-2024-6","article-title":"Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems","volume":"35","author":"Bernemann","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0460","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jmoldx.2016.08.003","article-title":"Analytical validation of androgen receptor splice variant 7 detection in a Clinical Laboratory Improvement Amendments (CLIA) laboratory setting","volume":"19","author":"Lokhandwala","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.eururo.2017.11.038_bib0465","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0470","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0475","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2017.11.038_bib0480","first-page":"78","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"110","author":"Wyatt","year":"2018","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.11.038_bib0485","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","article-title":"Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1","volume":"20","author":"Cai","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.11.038_bib0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biocel.2014.06.013","article-title":"Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells","volume":"54C","author":"Krause","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0495","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrurol.2015.184","article-title":"Prostate cancer: AR splice variant dimerization-clinical implications","volume":"12","author":"Antonarakis","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.11.038_bib0500","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1541-7786.MCR-16-0236","article-title":"Interplay between cytoplasmic and nuclear androgen receptor splice variants mediates castration resistance","volume":"15","author":"Zhan","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0505","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0510","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.11.038_bib0515","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","article-title":"Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex","volume":"28","author":"Heemers","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.eururo.2017.11.038_bib0520","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0525","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nprot.2016.020","article-title":"Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes","volume":"11","author":"Mohammed","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.eururo.2017.11.038_bib0530","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/nar\/gkw1162","article-title":"Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity","volume":"45","author":"McClurg","year":"2017","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0535","doi-asserted-by":"crossref","first-page":"691","DOI":"10.18632\/oncotarget.975","article-title":"Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors","volume":"4","author":"Gillis","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.11.038_bib0540","doi-asserted-by":"crossref","first-page":"17492","DOI":"10.1073\/pnas.1308587110","article-title":"gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer","volume":"110","author":"Nyquist","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.11.038_bib0545","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.11.038_bib0550","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-17-0320","article-title":"Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer","volume":"77","author":"Van Etten","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0555","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.11.038_bib0560","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1073\/pnas.0401123101","article-title":"Structural basis of androgen receptor binding to selective androgen response elements","volume":"101","author":"Shaffer","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.11.038_bib0565","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1535-7163.MCT-17-0259","article-title":"Bypassing drug-resistance mechanisms of prostate cancer with small-molecules that target androgen receptor chromatin interactions","volume":"16","author":"Dalal","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2017.11.038_bib0570","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1535-7163.MCT-16-0912","article-title":"Niclosamide and bicalutamide combination treatment overcomes enzalutamide and bicalutamide resistant prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2017.11.038_bib0575","doi-asserted-by":"crossref","first-page":"32210","DOI":"10.18632\/oncotarget.8493","article-title":"Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.11.038_bib0580","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0585","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1158\/1541-7786.MCR-17-0280","article-title":"variant-coactivator interactions to exploit prostate cancer vulnerabilities","volume":"15","author":"Magani","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.eururo.2017.11.038_bib0590","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/onc.2014.302","article-title":"Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression","volume":"34","author":"Jin","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2017.11.038_bib0595","doi-asserted-by":"crossref","first-page":"61955","DOI":"10.18632\/oncotarget.11326","article-title":"Activation of GRP\/GRP-R signaling contributes to castration-resistant prostate cancer progression","volume":"7","author":"Qiao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.11.038_bib0600","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 Is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817310308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817310308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:50Z","timestamp":1759583090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817310308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0302283817310308"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.11.038","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}